Fetuin-A and kidney function in persons with coronary artery disease - Data from the heart and soul study

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2144-2151

  Ix, Joachim H ^a,b   Chertow, Glenn M ^a,b   Shlipak, Michael G ^b,c   Brandenburg, Vincent M ^d   Ketteler, Markus ^d   Whooley, Mary A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Alpha 2 Heremans Schmid glycoprotein; Calcium; Chronic kidney disease; Fetuin A; Phosphorus; Vascular calcification

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C; FETUIN; FETUIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CORONARY RISK; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; UREMIA;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PROTEINS; CALCIUM; CHRONIC DISEASE; COHORT STUDIES; COMORBIDITY; CORONARY DISEASE; CREATININE; CYSTATIN C; CYSTATINS; DIABETES COMPLICATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OBESITY; PHOSPHORUS; PROSPECTIVE STUDIES; SAN FRANCISCO;

EID: 33748086765     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl204     Document Type: Article

References (46)

1. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [5 Suppl 3]: S112-S119
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
4. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1489-1496
5. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
6. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513
7. Alfrey AC, Ibels LS. Role of phosphate and pyrophosphate in soft tissue calcification. Adv Exp Med Biol 1978; 103: 187-193
8. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R. 3rd. Arterial calcification and pathology in uremic; patients undergoing dialysis. Am J Med 1979; 66: 790-796
9. Bostrom K, Demer LL. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr 2000; 10: 151-158
10. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int 2005; 94 [Suppl]: S120-S127
11. Ketteler M, Westenfeld R, Schlieper G, Brandenburg V, Floege J. 'Missing' inhibitors of calcification: General aspects and implications in renal failure. Pediatr Nephrol 2005; 20: 383-388
12. Jahnen-Dechent W, Schinke T, Trindl A et al. Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 1997; 272: 31496-31503
13. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996; 271: 20789-20796
14. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 2003; 361: 827-833
15. Beattie MS, Shlipak MG, Liu H, Browner WS, Schiller NB, Whooley MA. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: Data from the Heart and Soul Study. Circulation 2003; 107: 245-250
16. Ix JH, Shlipak MG, Liu HH, Schiller NB, Whooley MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: The heart and soul study. J Am Soc Nephrol 2003; 14: 3233-3238
17. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: The Heart and Soul Study. JAMA 2003; 290: 215-221
18. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929-937
19. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999; 59: 1-8
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
21. List of common abbreviations. Am J Kidney Dis 1999; 34 [2 Suppl 1]: S7-S8
22. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140
23. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
24. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
25. Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-223
26. London GM, Marchais SJ, Safar ME et al. Aortic and large artery compliance in end-stage renal failure. Kidney Int 1990; 37: 137-142
27. Lucas MF, Quereda C, Teruel JL, Orte L, Marcen R, Ortuno J. Effect of hypertension before beginning dialysis on survival of hemodialysis patients. Am J Kidney Dis 2003; 41: 814-821
28. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290
29. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566
30. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401
31. Stenvinkel P, Wang K, Qureshi AR et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392
32. Wang AY, Woo J, Lam CW et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 1676-1685
33. Heiss A, DuChesne A, Denecke B et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003; 278: 13333-13341
34. Moe SM, Reslerova M, Ketteler M, O'Neill K et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67: 2295-2304
35. Mehrotra R, Westenfeld R, Christenson P et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney Int 2005; 67: 1070-1077
36. Mathews ST, Singh GP, Ranalletta M et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002; 51: 2450-2458
37. Rokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C - a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998; 101: 875-881
38. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37: 79-83
39. Kramer H, Jacobs DR Jr, Bild D et al. Urine albumin excretion and subclinical cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis. Hypertension 2005; 46: 38-43
40. Newman DJ, Thakkar H, Edwards RG et al. Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312-318
41. Knight EL, Verhave JC, Spiegelman D et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421
42. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: Evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64: 1118-1129
43. Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu K. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet 2005; 116: 146-151
44. Westenfeld R, Smeets R, Schaefer C. The effect of fetuin-A, phosphate, and uremia on the induction of extraosseous calcification in mice. J Am Soc Nephrol 2004; 15: 270A
45. Ketteler M, Brandenburg V, Jahnen-Dechent W, Westenfeld R, Floege J. Do not be misguided by guidelines: The calcium x phosphate product can be a Trojan horse. Nephrol Dial Transplant 2005; 20: 673-677
46. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824